Independent · non-commercial · publishes on a quarterly cycle|Current cycle 2026 Q3
Methodology|Interests|Funding|Corrections
Compound Evidence InstituteEvidence synthesis · established 2023Graded assessments of compounds, trials, methods and supply
Document set current to 30 July 2026
Bibliographic record

Effect of continued weekly subcutaneous semaglutide vs placebo on weight loss maintenance in adults with…

Rubino D, Abrahamsson N, Davies M, Hesse D, Greenway FL, Jensen C, Lingvay I, Mosenzon O, Rosenstock J, Rubio MA, Rudofsky G…. JAMA 2021

Document identifier
CEI-BR-094
Series
Bibliographic record
Version
1.0
Published
30 Jul 2026
Last reviewed
30 Jul 2026
Certainty
Not rated

§1Bibliographic record

§1.1Record

Authors
Rubino D, Abrahamsson N, Davies M, Hesse D, Greenway FL, Jensen C, Lingvay I, Mosenzon O, Rosenstock J, Rubio MA, Rudofsky G, Tadayon S, Wadden TA, Dicker D
Title
Effect of continued weekly subcutaneous semaglutide vs placebo on weight loss maintenance in adults with overweight or obesity: the STEP 4 randomized clinical trial
Source
JAMA
Year
2021
Volume, issue, pages
325(14):1414–1425
Digital object identifier
10.1001/jama.2021.3224
PubMed identifier
33755728
Record type
Journal article
Institute identifier
CEI-BR-094

§1.2Institute documents citing this record

Table 1. Documents in the Institute set that cite this record.

DocumentSeries
Monograph: SemaglutideCompound monograph
Trial abstract: STEP-4Trial abstract
Synthesis: Glucagon-like peptide-1 receptor agonists for weight reduction in…Evidence synthesis
Synthesis: Weight change after discontinuation of an incretin receptor agonistEvidence synthesis
Synthesis: Semaglutide in obesity and overweight in adults: effect on the anchor…Evidence synthesis
Synthesis: Semaglutide in type 2 diabetes mellitus: effect on the anchor outcomeEvidence synthesis
Synthesis: Semaglutide in atherosclerotic cardiovascular disease and…Evidence synthesis
Synthesis: Semaglutide in heart failure with preserved ejection fraction and…Evidence synthesis
Synthesis: Semaglutide in obesity and overweight in adults: tolerability and…Evidence synthesis
Synthesis: Semaglutide in type 2 diabetes mellitus: tolerability and…Evidence synthesis
Synthesis: Semaglutide in atherosclerotic cardiovascular disease and…Evidence synthesis
Synthesis: Semaglutide in heart failure with preserved ejection fraction and…Evidence synthesis
Synthesis: Semaglutide in obesity and overweight in adults: durability of effectEvidence synthesis
Synthesis: Semaglutide in type 2 diabetes mellitus: durability of effectEvidence synthesis
14 citing documents.

§1.3Subject tags

semaglutide withdrawal STEP

Compound Evidence Institute · CEI-BR-094 · https://compoundevidence.com/bibliography/rubino2021/ · retrieved 30 July 2026
Nothing published by the Institute is medical advice, a diagnosis, a prescription, a treatment recommendation or a purchasing recommendation. Compounds supplied for research use are not approved for human or veterinary use in any jurisdiction, and a favourable analytical assessment of a supplier is not a statement that any product is safe or effective. The Institute publishes certainty ratings and never recommendations. No telephone number, messaging handle or ordering channel appears anywhere on this site.